25 results on '"Horwitz, S.M."'
Search Results
2. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma
3. E. coli dihydroorotate dehydrogenase bound to the inhibitor HMNQ
4. E. coli dihydroorotate dehydrogenase
5. LB1139 CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment
6. 024 - Outcomes and prognostic factors in African American/black patients with mycosis fungoides and Sézary syndrome
7. 1039TiP - Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
8. 335 Utility of imaging in cutaneous marginal zone lymphoma
9. 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
10. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30‐POSITIVE (CD30+) CUTANEOUS T‐CELL LYMPHOMA (CTCL).
11. INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORMED MARGINAL ZONE LYMPHOMA TREATED WITH RCHOP‐LIKE REGIMENS.
12. 944O - Brentuximab Vedotin in Combination with Chp in Patients (Pts) with Newly-Diagnosed Cd30+ Peripheral T-Cell Lymphomas (Ptcl): 2-Year Follow-Up
13. ANAPLASTIC LARGE CELL LYMPHOMA, ALK‐NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T‐CELL PROJECT.
14. RISK OF BREAST IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA‐ALCL) IN A COHORT OF 3546 WOMEN PROSPECTIVELY FOLLOWED AFTER RECEIVING TEXTURED BREAST IMPLANTS.
15. Duvelisib, an oral dual PI3K‐δ,γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial.
16. TREATMENT AND OUTCOMES OF PATIENTS WITH NK/T‐CELL LYMPHOMA TREATED WITH MODIFIED (m)SMILE AND INTENSITY‐MODULATED RADIOTHERAPY (IMRT), A SINGLE CENTER EXPERIENCE.
17. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
18. 9205 Pralatrexate treatment response by key baseline parameters in the pivotal, multi-center, phase 2 study in relapsed or refractory peripheral T-cell lymphoma (PROPEL)
19. Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.
20. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION.
21. IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT.
22. INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT-301, A NOVEL PYRROLOBENZODIAZAPINE-BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON-HODGKIN LYMPHOMA.
23. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA.
24. Treatment adherence and risk of death after a myocardial infarction
25. ABSTRACTS.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.